Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel de Paz, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Ángel Hernández-Rivas, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3764.

https://doi.org/10.1182/blood.V120.21.3764.3764

Published: 2012

Journal Articles

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel De Paz, MD, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Angel Hernandez-rivas, MD, Pilar Cano, Juan Luis Steegmann, MD, PhD

Blood (2012) 120 (21): 3768.

https://doi.org/10.1182/blood.V120.21.3768.3768

Published: 2012

Journal Articles

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Blood (2012) 120 (21): 3762.

https://doi.org/10.1182/blood.V120.21.3762.3762

Published: 2012

Journal Articles

Impact of Rituximab-Based Therapy After Histological Transformation on High-Dose Therapy and Autologous Stem Cell Transplantation in Follicular Transformed Lymphomas

Jose Manuel Calvo-Villas, Alejandro Martín, Carlos Panizo, MD, Juan Manuel Sancho, Alba Redondo, José David González-Sanmiguel, Blanca Sanchez Gonzalez, MD, Maria José Requena, Eva González-Barca, MD, María José Rodríguez-Salazar, Nerea Castro, Viviana Paredes, Jorge Gayoso, Dolores Caballero, MD

Blood (2011) 118 (21): 4478.

https://doi.org/10.1182/blood.V118.21.4478.4478

Published: 2011

Journal Articles

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Luis Felipe Casado, Isabel Massague, Pilar Giraldo, PhD, Manuel Perez-Encinas, Raquel De Paz, MD, Joaquín Martínez-López, Guiomar Bautista, Santiago Osorio, Maria José Requena, Luis Palomera, Maria Jesús Peñarrubia, Carmen Calle, Begoña Maestro, Juan Luis Steegmann, MD, PhD

Blood (2010) 116 (21): 1237.

https://doi.org/10.1182/blood.V116.21.1237.1237

Published: 2010

Journal Articles

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Jimena Cannata-Ortiz, Concepción Nicolás, Ana García-Noblejas, Javier Lopez, Maria José Requena, Concepción Alaez, Adrian Alegre, Reyes Arranz

Blood (2010) 116 (21): 2867.

https://doi.org/10.1182/blood.V116.21.2867.2867

Published: 2010

Journal Articles

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Luis Felipe Casado, MD, PhD, Isabel Massague, MD, Pilar Giraldo, MD, Manuel Pérez-Encinas, MD, Raquel de Paz, MD, PhD, Joaquin Martínez-López, MD, PhD, Rafael Fores, MD, Santiago Osorio, MD, Maria José Requena, MD, Luis Palomera, MD, María Jesus Peñarrubia, MD, Carmen Burgaleta, MD, PhD, Begoña Maestro, PhD, Juan Luis Steegmann, MD, PhD

Blood (2009) 114 (22): 1121.

https://doi.org/10.1182/blood.V114.22.1121.1121

Published: 2009

NARROW

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Impact of Rituximab-Based Therapy After Histological Transformation on High-Dose Therapy and Autologous Stem Cell Transplantation in Follicular Transformed Lymphomas

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Email alerts

ASH Publications

American Society of Hematology

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Impact of Rituximab-Based Therapy After Histological Transformation on High-Dose Therapy and Autologous Stem Cell Transplantation in Follicular Transformed Lymphomas

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only